In this study, we demonstrated that ING1 was a favorable prognostic factor for GBM patients and that NTZ, which was previously used as an antiparasitic drug, could significantly inhibit glioma cells by upregulating transcription of the target gene, ING1, and decreasing autophagic degradation of ING1. The gene discussed is ING1; the disease is central nervous system cancer.